GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cresco Labs Inc (OTCPK:CRLBF) » Definitions » Capital Expenditure

Cresco Labs (Cresco Labs) Capital Expenditure : $-43.29 Mil (TTM As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Cresco Labs Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Cresco Labs's cash flow for capital expenditures for the three months ended in Mar. 2024 was $-6.6 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was $-43.29 Mil.

Cresco Labs Capital Expenditure Historical Data

The historical data trend for Cresco Labs's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cresco Labs Capital Expenditure Chart

Cresco Labs Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -96.13 -89.26 -97.05 -86.13 -57.88

Cresco Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.15 -18.19 -13.37 -5.18 -6.55

Cresco Labs Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cresco Labs (Cresco Labs) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cresco Labs Inc (OTCPK:CRLBF) » Definitions » Capital Expenditure
Comparable Companies
TSX:DHT.U NEOE:GLAS.A.U TSX:WEED TSX:TSND TSX:GUD TSX:CRON TSX:ACB XCNQ:AAWH.U XCNQ:AYR.A TSX:OGI ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
6CQ:Germany CL:Canada
Address
400 W. Erie Street, Suite 110, Chicago, IL, USA, 60654
Website
https://www.crescolabs.com
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products through Sunnyside, Cresco Labs' national dispensary brand and third-party retail stores. The Company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis.